Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
pixel

NASDAQ:CNTG - Centogene Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.67
  • Forecasted Upside: 83.55 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.17
▼ -0.38 (-3.60%)
1 month | 3 months | 12 months
Get New Centogene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.67
▲ +83.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Centogene in the last 3 months. The average price target is $18.67, with a high forecast of $22.00 and a low forecast of $15.00. The average price target represents a 83.55% upside from the last price of $10.17.
Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
pixel

Buy

The current consensus among 4 investment analysts is to buy stock in Centogene.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2021Robert W. BairdReiterated RatingBuy$19.00High
i
12/16/2020SVB LeerinkReiterated RatingOutperformHigh
i
Rating by P. Souda at SVB Leerink LLC
11/5/2020Credit Suisse GroupInitiated CoverageOutperform$15.00High
i
10/7/2020Kempen & CoInitiated CoverageBuy$22.00Medium
i
4/24/2020Robert W. BairdBoost Price TargetOutperform$15.00 ➝ $20.00Medium
i
4/24/2020BTIG ResearchBoost Price TargetBuy$18.00 ➝ $23.00Low
i
Rating by Sung Ji Nam at BTIG Research
12/3/2019Robert W. BairdInitiated CoverageOutperform$15.00Medium
i
12/2/2019SVB LeerinkReiterated RatingOutperformHigh
i
Rating by P. Souda at SVB Leerink LLC
12/2/2019Evercore ISIInitiated CoverageOutperform$17.00High
i
12/2/2019BTIG ResearchInitiated CoverageBuy$18.00High
i
(Data available from 6/16/2016 forward)
Centogene logo
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Read More

Today's Range

Now: $10.17
$10.05
$10.50

50 Day Range

MA: $10.44
$9.02
$12.93

52 Week Range

Now: $10.17
$8.61
$27.10

Volume

65,044 shs

Average Volume

58,774 shs

Market Capitalization

$201.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Centogene?

The following equities research analysts have issued reports on Centogene in the last year: Credit Suisse Group AG, Kempen & Co, Robert W. Baird, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CNTG.

What is the current price target for Centogene?

3 Wall Street analysts have set twelve-month price targets for Centogene in the last year. Their average twelve-month price target is $18.67, suggesting a possible upside of 83.5%. Kempen & Co has the highest price target set, predicting CNTG will reach $22.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $15.00 for Centogene in the next year.
View the latest price targets for CNTG.

What is the current consensus analyst rating for Centogene?

Centogene currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNTG will outperform the market and that investors should add to their positions of Centogene.
View the latest ratings for CNTG.

What other companies compete with Centogene?

How do I contact Centogene's investor relations team?

Centogene's physical mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The company's listed phone number is 49-3818-011-3500 and its investor relations email address is [email protected]com. The official website for Centogene is www.centogene.com.

Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
pixel